This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Classification of pre-eclampsia into early and late pre-eclampsia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The terms early versus late pregnancy is becoming widely accepted as a better indicator of disease significance than the classic terms "mild" or "severe" pre-eclamsia (1).

There is evidence that early onset (before 34 weeks of gestation) is associated with severe pre-eclamsia.

  • early onset pre-eclamsia is thought to be due to involvement of the placenta with associated
    • abnormal uterine artery Doppler flow
    • fetal growth restriction
    • adverse maternal and fetal outcomes
  • late onset pre-eclampsia (after 34 weeks of gestation) appears to be due to maternal "constitutional" factors, such as body mass index (BMI) and is considered to be associated with a more favorable outcome

Other than the aetiology of the disease, maternal haemodynamics appear to vary according to the time of presentation. A study conducted with 1345 nulliparous patients identified as normotensive with bilateral uterine notching at 20-22 weeks' gestation found out that

  • women with early disease had higher total vascular resistance and lower cardiac output
  • while late onset women had higher pre-pregnancy BMI, higher cardiac output, and lower total vascular resistance when compared with the early onset and control patients (1)

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.